Table 5.
Incidence of IDH mutations in AML patients from various countries
| Country | No. IDH1m/all cases (%) | No. of IDH1m/CN-AML (%) | No. IDH2m/all cases (%) | No. of IDH2m/CN-AML (%) |
|---|---|---|---|---|
| ASIA | ||||
| Taiwan | ||||
| Chou W et al.(2010) [18] | 27/493 (5.5) | 20/227 (8.8) | ND | ND |
| China | ||||
| Zou Y et al.(2010) [28] | 4/68 (5.9) | ND | 4/48 (8.3) | ND |
| Zhang Y et al.(2011) [32] | 23/365 (6.3) | 6/111 (5.4) | ND | ND |
| Lin J et al.(2011) [31] | 4/110 (3.6) | ND | ND | ND |
| Thailand | ||||
| This study | 20/230 (8.7) | 11/126 (8.7) | 24/230 (10.4) | 12/126 (9.5) |
| EUROPE‡ [21,23-27,30,41] | 6.0-10.9 | 9.4-16.0 | 2.0*-10.9 | 3.2*-15.2 |
| NORTH AMERICA∫ | 2.2-13.7 | 4.9-16.0 | 1.3*-19.2 | 2.4*-19.2 |
| [5,15,19,20,22,29] |
*The authors only identified IDH2 R172K but did not include IDH2 R140Q mutation; † Pediatric acute myeloid leukemia; ‡ All studies reported during 2010-2011; ∫ All studies reported during 2009-2011; ND, not determined